Development of the Genotyping Protocol for the Study of Genetic Polymorphisms of CYP450 2C9 (CYP2C9 * 2, * 3) and VKORC1 1639G> A
AbstractTwo genes are mainly involved in the variability of the response to Acenocoumarol: one encoding the vitamin K epoxide reductase (VKORC1) pharmacological target of AVKs, and the other encoding the cytochrome P450 2C9 (CYP2C9), responsible for the metabolism of coumarin derivatives to inactive metabolites.The objective of our work is to develop a genotyping technique in order to study this genetic polymorphism within the Algerian population.Genotyping is performed by RFLP (restriction fragment length polymorphism) PCR over 4 steps: DNA extraction, amplification, enzymatic digestion and electrophoresis. The FDA has approved that the use of genetic testing may help healthcare professionals better predict steady-state doses of vitamin k antagonists in order to optimize the management of patients treated with this drug.
. Tom Schalekamp, et al. Acenocoumarol stabilization is delayed in CYP2C9*3 carriers. Clinical pharmacology and therapeutics.2004; 75(5):394-402.
. T. I. VERHOEF, et al. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. Journal of Thrombosis and Haemostasis, 10: 606–614 DOI: 10.1111/j.1538-7836.2012.04633.x.
. Jonatan D et al. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clinical Pharmacology & Therapeutics 2005; 78(5):540-50.
. Jose´ Hermida, et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood, 1 June 2002, Volume 99, Number 11.
. Loes E. Visser et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C92 or CYP2C93 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004, 14:27–33.
. F. Z. Smires et al. Inﬂuence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 594–598
. Allan E. Rettie et al. A case study of acenocoumarol sensitivity and genotypephenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. British Journal of Clinical Pharmacology. DOI:10.1111/j.1365-2125.2006.02688.x
. Anupriya Kaur, et al. Cytochrome P450 (CYP2C9 * 2, * 3) & vitamin-K epoxide reductase complex (VKORC1 -1639G
. Laurent Bodin et al. CytochromeP4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood, 1 July 2005, Volume 106, Number 1.
. ElizabethA. Sconce et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 1 October 2005. Volume 106, Number 7.
Copyright (c) 2020 American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.